Stanislas Pol

42.7k total citations · 5 hit papers
484 papers, 18.9k citations indexed

About

Stanislas Pol is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Stanislas Pol has authored 484 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 423 papers in Hepatology, 357 papers in Epidemiology and 72 papers in Infectious Diseases. Recurrent topics in Stanislas Pol's work include Hepatitis C virus research (378 papers), Liver Disease Diagnosis and Treatment (267 papers) and Hepatitis B Virus Studies (242 papers). Stanislas Pol is often cited by papers focused on Hepatitis C virus research (378 papers), Liver Disease Diagnosis and Treatment (267 papers) and Hepatitis B Virus Studies (242 papers). Stanislas Pol collaborates with scholars based in France, United States and Germany. Stanislas Pol's co-authors include Anaïs Vallet‐Pichard, Bertrand Nalpas, Vincent Mallet, Christian Bréchot, Hélène Fontaine, Virginie Verkarre, Valérie Dhalluin-Venier, P. Cacoub, Marc Bourlière and Valérie Thiers and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Stanislas Pol

460 papers receiving 18.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FIB-4

2007 1.6k citations Anaïs Vallet‐Pichard, Vincent Mallet et al. Hepatology profile →
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 771 citations Christophe Hézode, Stanislas Pol et al. profile →
Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

2002 530 citations Stanislas Pol et al. profile →
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

2015 477 citations Annette Bruchfeld, Stanislas Pol et al. profile →
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

2017 271 citations Eric Lawitz, Stanislas Pol et al. profile →

Peers

Countries citing papers authored by Stanislas Pol

Since Specialization

Citations

This map shows the geographic impact of Stanislas Pol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanislas Pol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanislas Pol more than expected).

Fields of papers citing papers by Stanislas Pol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanislas Pol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanislas Pol. The network helps show where Stanislas Pol may publish in the future.

Co-authorship network of co-authors of Stanislas Pol

This figure shows the co-authorship network connecting the top 25 collaborators of Stanislas Pol. A scholar is included among the top collaborators of Stanislas Pol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanislas Pol. Stanislas Pol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural basis for hepatitis E virus neutralization by potent human antibodies 2025 ·Science Advances ·(unknown), Eduard Baquero, Cyril Planchais, Virginie Doceul, Hicham El Costa, Estelle Mottez, Vincent Mallet, Stanislas Pol, Matthew L. Albert, (unknown), Cécile Alanio, Jordan D. Dimitrov, Hugo Mouquet	0
2	Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis 2023 ·Alimentary Pharmacology & Therapeutics ·Thierry Poynard, Olivier Deckmyn, Valentina Peta, Valérie Paradis, Jean–François Gautier, (unknown), Pierre Bédossa, Laurent Castéra, Stanislas Pol, Dominique Valla	5
3	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline 2023 ·Annals of Internal Medicine ·Ahmed A. Awan, Marina Berenguer, Annette Bruchfeld, Fabrizio Fabrizi, David S. Goldberg, Jidong Jia, Nassim Kamar, Rosmawati Mohamed, Mário Guimarães Pessôa, Stanislas Pol, Meghan E. Sise, Ethan M. Balk, Craig E. Gordon, Gaelen P. Adam, Michael Cheung, Amy Earley, Paul Martin, Michel Jadoul	5
4	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management 2021 ·Cancer Prevention Research ·Pierre Nahon, Richard Layese, Carole Cagnot, Tarik Asselah, Dominique Guyader, Stanislas Pol, Georges‐Philippe Pageaux, Victor de Lédinghen, Denis Ouzan, Fabien Zoulim, Étienne Audureau	1
5	Direct, indirect and total effect of HIV coinfection on the risk of non‐liver‐related cancer in hepatitis C virus‐infected patients treated by direct‐acting antivirals: a mediation analysis 2021 ·HIV Medicine ·(unknown), Stanislas Pol, Philippe Sogni, Hélène Fontaine, Karine Lacombe, Jean‐Marc Lacombe, (unknown), Céline Dorival, Marc Bourlière, Firouzé Bani‐Sadr, Victor de Lédinghen, David Zucman, Dominique Larrey, Dominique Salmon, Fabrice Carrat, Linda Wittkop, (unknown), (unknown)	1
6	Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers 2020 ·The Journal of Experimental Medicine ·(unknown), Maxime Beretta, Maryline Bourgine, Malika Ait‐Goughoulte, Cyril Planchais, (unknown), (unknown), Valérie Lorin, (unknown), (unknown), Oriane Fiquet, Jordan D. Dimitrov, Marie‐Louise Michel, Marie‐Noëlle Ungeheuer, Camille Sureau, Stanislas Pol, James P. Di Santo, Hélène Strick‐Marchand, Nadège Pelletier, Hugo Mouquet	44
7	L’index FIB-4 pour faire le diagnostic de fibrose hépatique avancée au cours de la stéatose hépatique 2019 ·La Presse Médicale ·Vincent Mallet, Lucia Parlati, Anaïs Vallet‐Pichard, Benoît Terris, Emmanuel Tsochatzis, Philippe Sogni, Stanislas Pol	5
8	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure 2017 ·Hepatology ·Fred Poordad, Stanislas Pol, Armen Asatryan, Marı́a Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert Reindollar, Stuart C. Gordon, Stephen Pianko, Michael Fried, David Bernstein, Joel E. Gallant, Chih‐Wei Lin, Lei Yang, Teresa I. Ng, Preethi Krishnan, (unknown), Jens Kort, Federico Mensa	105
9	The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study 2015 ·Liver International ·Zobair M. Younossi, Maria Stepanova, Stanislas Pol, Jean–Pierre Bronowicki, Patrizia Carrieri, Marc Bourlière	45
10	Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN 2014 ·Gut ·Hélène Fontaine, Sandrine Kahi, Cyrille Chazallon, Maryline Bourgine, Anne Varaut, C Buffet, Ophélie Godon, Jean–François Méritet, Y Saïdi, Marie‐Louise Michel, Daniel Scott‐Algara, J.-P. Aboulker, Stanislas Pol	78
11	Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study 2014 ·Liver International ·Thomas Berg, Pietro Andreoné, Stanislas Pol, Stuart K. Roberts, Zobair M. Younossi, M. Diago, Eric Lawitz, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon‐Domanec, Ralph DeMasi, Gastón Picchio, Donghan Luo, Sandra De Meyer, Stefan Zeuzem	5
12	1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016) 2013 ·Journal of Hepatology ·J.‐P. Bronowicki, Vlad Ratziu, Adrián Gadano, Paul J. Thuluvath, Fernando Bessone, Claudia Martorell, Stanislas Pol, Rubén Terg, Ziad Younes, Bing He, Timothy Eley, David Cohen, Patricia Méndez, Eric Hughes	10
13	5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN 2011 ·Journal of Hepatology ·Stefan Zeuzem, Pietro Andreoné, Stanislas Pol, E.J. Lawitz, M. Diago, S. Roberts, Roberto Focaccia, Z.M. Younossi, Graham R. Foster, (unknown), Paul J. Pockros, (unknown), Sebastian Meyer, (unknown), Gastón Picchio, Maria Beumont	23
14	406 SUPERSONIC SHEAR IMAGING IS A NEW POTENT MORPHOLOGICAL NON-INVASIVE TECHNIQUE TO ASSESS LIVER FIBROSIS. PART I: TECHNICAL FEASABILITY 2010 ·Journal of Hepatology ·Éric Bavu, Jean‐Luc Gennisson, Vincent Mallet, Bruno-Félix Osmanski, Mathieu Couade, Jérémy Bercoff, Mathias Fink, Philippe Sogni, Anaïs Vallet‐Pichard, Bertrand Nalpas, Mickaël Tanter, Stanislas Pol	4
15	Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a 2008 ·PLoS ONE ·(unknown), (unknown), (unknown), Claire Rekacewicz, (unknown), Sherif A. El‐Kafrawy, (unknown), Mohamed Abdel-Hamid, Gamal Esmat, Stanislas Pol, Arnaud Fontanet, (unknown)	16
16	Expression of Defective Hepatitis B Virus Particles Derived from Singly Spliced RNA Is Related to Liver Disease 2008 ·The Journal of Infectious Diseases ·Patrick Soussan, Jonathan Pol, Florianne Garreau, Véronique Schneider, Catherine Le Pendeven, Bertrand Nalpas, Karine Lacombe, Philippe Bonnard, Stanislas Pol, Dina Kremsdorf	52
17	Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C 2008 ·Journal of Hepatology ·Matthew L. Albert, Jérémie Decalf, Stanislas Pol	17
18	Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. 2007 ·PubMed ·(unknown), (unknown), Gamal Esmat, (unknown), (unknown), Claire Rekacewicz, (unknown), Khaled Zalata, Mohamed Abdel-Hamid, Pierre Bédossa, Stanislas Pol, M.K. Mohamed, Arnaud Fontanet	40
19	[Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance]. 2002 ·PubMed ·Stanislas Pol	0
20	Immune therapy of hepatitis B virus (HBV) chronic infection. European experience. 2000 ·PubMed ·Stanislas Pol, Marie‐Louise Michel, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact